Leap Therapeutics (NASDAQ:LPTX) lost 63% in the premarket on Tuesday after the antibody-based drug developer announced that it would not advance its lead candidate, sirexatamab, in Phase 3 studies for ...

Antibody engineering is a rapidly evolving field that focuses on the design and development of antibodies for therapeutic and diagnostic purposes. Recent advancements in this area have led to the ...

Recule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several ...

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...